Acquisitions and Strategic Partnerships - The company has completed acquisitions of 100% of MiJian Information and ShenZhou Vision, and 70% of Shanghai JinChuang, enhancing its position in the medical information technology sector[6]. - The company aims to strengthen strategic partnerships with domestic platform vendors to promote localization efforts and improve service competitiveness[9]. - The company has made strategic acquisitions to enhance its capabilities in the healthcare sector, including the acquisition of Shanghai Jinchuang Information Technology Co., Ltd.[110]. Financial Performance - The company's operating revenue for 2020 was RMB 787,896,467.61, representing an increase of 8.86% compared to RMB 723,766,459.30 in 2019[20]. - The net profit attributable to shareholders for 2020 was RMB 80,368,462.37, an increase of 86.24% from RMB 43,153,626.44 in 2019[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 72,050,661.62, up 74.20% from RMB 41,361,918.65 in 2019[20]. - The net cash flow from operating activities for 2020 was RMB 113,833,220.60, a 41.75% increase from RMB 80,302,890.18 in 2019[20]. - The total assets at the end of 2020 were RMB 1,982,963,071.10, reflecting a growth of 24.09% from RMB 1,597,976,549.12 at the end of 2019[20]. - The net assets attributable to shareholders at the end of 2020 were RMB 1,365,823,220.26, an increase of 25.33% from RMB 1,089,816,314.06 at the end of 2019[20]. - The basic earnings per share for 2020 was RMB 0.1403, representing a growth of 76.48% compared to RMB 0.0795 in 2019[20]. - The diluted earnings per share for 2020 was RMB 0.1395, an increase of 75.69% from RMB 0.0794 in 2019[20]. - The weighted average return on equity for 2020 was 6.58%, an increase of 2.42 percentage points from 4.16% in 2019[20]. - The company reported a net profit of RMB 62,214,643.82 in Q4 2020, significantly improving from previous quarters[22]. Revenue and Market Trends - The company achieved a main business revenue of 787.90 million yuan, representing a year-on-year growth of 8.86%[48]. - Revenue from the healthcare sector reached ¥436.53 million, accounting for 55.40% of total revenue, with a year-on-year growth of 15.49%[58]. - The company reported a 10% increase in overall revenue for the last fiscal year, reaching $200 million, driven by strong sales in its software solutions[40]. - The company is aware of the risks posed by global economic slowdowns and geopolitical tensions, which may impact IT demand and market competition[9]. - The smart healthcare market in China has achieved a CAGR of 18% over the past 7 years, with the market size reaching nearly 50 billion yuan in 2018[114]. - The projected market size for smart healthcare in China is expected to reach 59.5 billion yuan in 2020 and 79.2 billion yuan by 2023, indicating significant growth potential[114]. Research and Development - The company is investing heavily in R&D, with a budget allocation of $50 million for the development of new AI-driven healthcare analytics tools aimed at improving patient outcomes[42]. - The company has registered 131 new software copyrights during the reporting period, enhancing its intellectual property portfolio[39]. - The company has introduced a series of core business systems for smart cities, receiving positive feedback from the market and users[35]. - The company is actively leading innovation in smart healthcare, leveraging core technologies such as big data, cloud computing, and artificial intelligence[49]. - The company has established strategic development centers for cloud services and smart healthcare, accelerating the construction of new mechanisms and systems[49]. Operational Efficiency and Employee Management - The company is committed to improving employee retention through enhanced compensation and career development opportunities amid increasing competition for talent[6]. - The company has implemented a performance assessment system to enhance project management and customer satisfaction, resulting in improved project delivery efficiency[51]. - The company will focus on developing talent potential and establishing a learning organization to enhance overall employee quality and capabilities[129]. - The performance evaluation system will integrate market efforts, product innovation, and management innovation into year-end assessments, ensuring a multi-level incentive mechanism is effectively implemented[129]. Technology and Service Innovation - The company is actively exploring new service models to increase user engagement and brand value in response to evolving customer demands[4]. - The Smart Hospital solution integrates data-driven approaches with AI and blockchain technologies, aiming to enhance hospital information systems[30]. - The Zhihui Cloud platform is designed to support digital transformation across various industries, including finance, education, and healthcare, with a focus on cloud migration and management[32]. - The company is focusing on creating an open and collaborative ecosystem with IT partners to enhance service offerings and drive innovation[119]. - The company aims to enhance its cloud-based services, with a projected 30% increase in cloud service revenue driven by the growing demand for remote healthcare solutions[42]. Financial Management and Investments - The company has engaged in structured deposits with a range of interest rates from 3.20% to 3.70% across various time frames[176]. - The company has maintained a focus on low-risk financial products, ensuring capital preservation while seeking returns[176]. - The total amount of entrusted financial management reached 23,800.00 million, with no overdue amounts reported[176]. - The company has not reported any losses from its financial management activities, showcasing effective risk management practices[176]. - The company has successfully replaced pre-invested funds with raised funds amounting to CNY 9,072.20 million and CNY 2,073.95 million in two separate instances[104]. Shareholder and Equity Management - The company has implemented an equity incentive plan with a lock-up period of 12, 24, and 36 months for the granted restricted stocks[144]. - The company has established a profit compensation agreement for the acquisition projects, ensuring accountability for performance targets[146]. - The total number of ordinary shareholders at the end of the reporting period was 23,110, an increase from 15,576 at the end of the previous month[197]. - The company’s stock structure changed due to the lifting of restrictions on 41,697,950 shares, impacting the shareholding distribution[190]. - The company has committed to ensuring that no related party transactions will occur that could harm the interests of the company and its shareholders[141]. Compliance and Regulatory Commitments - The company will strictly adhere to the regulations set forth by the China Securities Regulatory Commission and other relevant authorities[141]. - The company has committed to not engaging in any competing business activities during the reporting period[144]. - The company has ensured that all commitments regarding avoiding competition and related party transactions have been fulfilled by the expiration date[143]. - The company guarantees compliance with relevant regulations and will not seek undue benefits through related party transactions[142].

Financial Performance - Net profit attributable to shareholders increased by 224.16% to CNY 8,364,642.84 for the current period[7] - Operating revenue for the current period reached CNY 199,524,143.52, reflecting a growth of 20.33% year-on-year[7] - The net cash flow from operating activities improved by 275.92% to CNY 34,159,003.93[7] - Basic earnings per share rose by 208.51% to CNY 0.0145[7] - The company reported a net profit excluding non-recurring gains and losses of CNY 8,329,977.25, up 259.15% year-on-year[7] - Total operating revenue for Q3 2020 was CNY 199,524,143.52, an increase of 20.34% compared to CNY 165,809,329.03 in the same period last year[40] - Net profit for Q3 2020 reached CNY 12,026,515.70, compared to CNY 2,880,655.65 in Q3 2019, representing a significant increase of 318.36%[42] - The company reported a comprehensive income total of CNY 11,611,831.95 for Q3 2020, compared to CNY 3,182,702.32 in the previous year, indicating a growth of 264.06%[42] - The company’s total revenue for the year-to-date period was ¥480,623,037.81, an increase of 4.5% from ¥460,593,222.00 in the previous year[46] - Net profit for the year-to-date period was ¥28,519,947.65, up 132.9% from ¥12,310,491.97 in the previous year[47] Assets and Liabilities - Total assets increased by 17.48% to CNY 1,877,299,309.61 compared to the end of the previous year[7] - The company's total assets reached CNY 1,877,299,309.61, an increase from CNY 1,597,976,549.12 at the end of 2019, representing a growth of approximately 17.5%[31] - The company's total liabilities amounted to CNY 508,694,714.52, slightly up from CNY 501,722,804.03, showing a marginal increase of about 1.4%[34] - Total liabilities decreased to CNY 340,121,916.01 in Q3 2020 from CNY 369,527,153.43 in Q3 2019, a reduction of 7.88%[38] - Total current assets decreased by 1.34% from 932,801,653.70 to 920,439,472.31[61] - Total non-current assets increased by 0.22% from 665,174,895.42 to 666,645,768.45[62] - Total liabilities increased by 0.47% from 501,722,804.03 to 504,069,352.88[63] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,142[10] - The largest shareholder, Liaoning Guoke Industrial Co., Ltd., holds 22.85% of the shares, totaling 136,529,042 shares[10] - The company has a total of 69,222,369 shares under lock-up agreements, including 50,639,258 shares from other shareholders[14] - The company plans to unlock 25% of restricted shares annually for executives, with specific unlock dates for various shareholders[14] Cash Flow and Investments - The company's cash and cash equivalents decreased by 42.97% to ¥163,051,656.28 due to increased cash payments for investments[18] - Cash and cash equivalents at the end of the period totaled 158,424,921.19, up from 76,933,026.19, marking an increase of approximately 106.5%[55] - The cash flow from investing activities was -150,619,489.50, slightly better than -161,356,546.68 in the previous year, indicating a reduction in cash outflow of about 6.5%[55] - Cash flow from financing activities generated a net inflow of 87,159,897.48, down from 168,799,846.48, reflecting a decrease of approximately 48.3%[55] Expenses and Costs - Total operating costs for Q3 2020 were CNY 185,756,455.10, up from CNY 159,859,190.84, reflecting a year-over-year increase of 16.25%[41] - Research and development expenses for Q3 2020 were CNY 18,549,795.79, which is a 103.06% increase from CNY 9,137,128.58 in the same quarter last year[41] - The company reported a 430.95% increase in income tax expenses to ¥5,179,938.11 due to higher profits leading to increased tax provisions[20] - Financial expenses decreased by 30.06% to ¥3,997,841.40, resulting from reduced borrowings and corresponding interest expenses[20] Other Financial Information - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[11] - The company did not engage in any share repurchase activities during the reporting period[33] - There were no significant non-operating fund occupations by controlling shareholders or related parties during the reporting period[26] - The report was not audited, which may affect the reliability of the financial data presented[71] - The company has adopted new revenue and lease standards, impacting the financial reporting[70]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥281,098,894.29, a decrease of 4.64% compared to ¥294,783,892.97 in the same period last year[20]. - The net profit attributable to shareholders of the listed company increased by 9.59% to ¥9,789,175.71, up from ¥8,932,140.63 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was ¥7,341,650.23, a decrease of 15.70% compared to ¥8,708,777.87 in the same period last year[20]. - The net cash flow from operating activities improved to -¥94,245,872.85, an 8.74% improvement from -¥103,269,382.44 in the previous year[20]. - The company's total revenue for the reporting period was CNY 281.10 million, a year-on-year decrease of 4.64%[41]. - The net profit attributable to shareholders was CNY 9.79 million, a year-on-year increase of 9.59%[41]. - The company's total operating revenue for the first half of 2020 was CNY 281,098,894.29, a decrease of 4.8% compared to CNY 294,783,892.97 in the first half of 2019[169]. - Net profit for the first half of 2020 was CNY 16,493,431.95, representing a significant increase of 74.1% compared to CNY 9,429,836.32 in the same period of 2019[171]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,780,068,571.85, an increase of 11.40% from ¥1,597,976,549.12 at the end of the previous year[20]. - The net assets attributable to shareholders of the listed company increased by 9.82% to ¥1,196,828,897.29 from ¥1,089,816,314.06 at the end of the previous year[20]. - The company's cash and cash equivalents decreased significantly from ¥285,888,396.42 to ¥122,882,742.92, a decline of approximately 57.0%[159]. - Total liabilities increased to ¥542,064,116.21 from ¥501,722,804.03, marking a rise of approximately 8.0%[162]. - The company's equity attributable to shareholders increased to ¥1,196,828,897.29 from ¥1,089,816,314.06, representing a growth of about 9.8%[163]. - The company's goodwill increased significantly from ¥329,950,878.75 to ¥474,465,370.09, reflecting an increase of approximately 43.8%[160]. Segment Performance - The company operates primarily in two segments: Smart Healthcare and Health Data, and Zhihui Cloud, providing efficient medical information software and cloud value-added services[27]. - The Smart Healthcare segment includes clinical application products and a data-driven new generation smart hospital solution, leveraging big data, AI, and blockchain technologies[28]. - The health data service segment generated revenue of ¥136,206,795.43, a decrease of 12.08% year-on-year, while the smart cloud service segment increased by 3.61% to ¥144,352,772.82[50]. - The government sector revenue surged by 97.39% to ¥56,010,336.66, with a gross margin of 11.48%[51]. Investments and Acquisitions - The company acquired a 70% stake in Shanghai Jinchuang Information Technology Co., Ltd. for 21 million yuan, enhancing its service capabilities[33]. - The company added 33 software copyrights during the reporting period, enhancing its intellectual property portfolio[36]. - The company completed acquisitions of Shanghai Mijian, Beijing Shenzhou Shihan, and Shanghai Jinchang, enhancing its market position in the medical information sector[87]. Research and Development - Research and development expenses decreased by 13.28% to ¥27,245,741.85 from ¥31,417,429.21 in the previous year[48]. - The company is committed to developing new technologies and products, focusing on smart city solutions and enhancing its cloud service offerings[31]. - The company aims to establish itself as a leading vendor in the medical informationization sector, leveraging technologies like 5G and big data[42]. - The company has filed for 2 new patents during the reporting period, further strengthening its innovation capabilities[38]. Market Strategy and Risks - The company faces market competition risks, emphasizing the need for technological and business model innovations to maintain competitiveness[84]. - Seasonal fluctuations in revenue are noted, with significant income typically realized in the fourth quarter, leading to potential cash flow risks[84]. - The COVID-19 pandemic has temporarily impacted operational performance, but it is anticipated to accelerate the development of medical information technology in the long term[88]. - The company plans to strengthen strategic cooperation with domestic platform manufacturers to expand customer resources and promote localization[89]. Shareholder and Equity Information - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[7]. - The total number of ordinary shareholders at the end of the reporting period is 19,556[142]. - The largest shareholder, Liaoning Guoke Industrial Co., Ltd., holds 25.60% of the shares, totaling 147,279,042 shares[142]. - The company has implemented an employee stock ownership plan with a total funding not exceeding RMB 60 million, allowing for the subscription of up to 3.780718 million shares[102]. Legal and Compliance - There are no significant litigation or arbitration matters reported during the period[99]. - The company has not undergone any bankruptcy restructuring during the reporting period[98]. - The half-year financial report has not been audited[97].

Financial Performance - Total revenue for the first quarter was ¥96,971,018.34, a decrease of 29.49% compared to ¥137,522,293.94 in the same period last year[8] - Net profit attributable to shareholders was -¥14,813,929.04, representing a decline of 310.49% from ¥7,037,897.03 in the previous year[8] - Basic and diluted earnings per share were both -¥0.0264, down 297.01% from ¥0.0134 in the same period last year[8] - Revenue for the first quarter was 96,971,018.34 CNY, a decrease of 29.49% year-on-year, while net profit attributable to shareholders was -14,813,929.04 CNY, a decline of 310.49% year-on-year[19] - The company reported a net loss of CNY 14,867,742.56 for Q1 2020, compared to a profit of CNY 8,018,602.56 in Q1 2019[47] - The total comprehensive income for Q1 2020 was -¥12,440,323.07, down from ¥3,126,333.31 in Q1 2019[50] Cash Flow and Liquidity - The net cash flow from operating activities was -¥140,432,508.14, which is a 16.85% increase in negative cash flow compared to -¥120,178,803.19 last year[8] - Cash and cash equivalents decreased by 55.51% compared to the beginning of the period, primarily due to net cash outflow from operating activities[16] - The cash flow from operating activities showed a net outflow of -¥140,432,508.14, worsening from -¥120,178,803.19 in the same period last year[53] - Total cash and cash equivalents at the end of the period were 32,526,333.82 CNY, down from 55,852,601.78 CNY in the previous period, reflecting a significant decrease in liquidity[57] - The company reported a significant decrease in cash and cash equivalents net increase of -111,887,862.73 CNY compared to -53,690,792.44 CNY in the previous period, indicating worsening cash flow conditions[57] Assets and Liabilities - Total assets increased by 8.26% to ¥1,729,910,580.08 from ¥1,597,976,549.12 at the end of the previous year[8] - The total liabilities of the company were CNY 513,904,245.32, slightly up from CNY 501,722,804.03, showing a marginal increase of about 2.4%[40] - The company's total liabilities were CNY 386,731,722.22, up from CNY 369,527,153.43 at the end of 2019, indicating a rise of 3.2%[44] - The total assets decreased to 1,597,976,549.12 CNY from 1,587,085,240.76 CNY, reflecting a slight decline in overall asset value[61] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,435[11] - The largest shareholder, Liaoning Guoke Industrial Co., Ltd., holds 25.60% of the shares, totaling 147,279,042 shares[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] Government Support and Other Income - The company received government subsidies amounting to ¥1,677,677.87 during the reporting period[9] - Other income increased by 488.98% year-on-year, mainly due to an increase in government subsidies received[17] Operational Challenges and Risks - The company faces risks related to market competition, seasonal fluctuations, and human resources, and is implementing strategies to mitigate these risks[21][22][23] - The company has completed acquisitions of 100% stakes in MiJian Information and Shenzhou Vision, which will expand its asset scale and business scope, potentially enhancing profitability and core competitiveness[25] - The company is facing strategic risks due to global economic slowdowns and geopolitical tensions, which may affect domestic IT demand and increase market competition[26] Acquisitions and Integration - The integration of acquired companies will focus on optimizing product structure and enhancing operational stability to mitigate risks associated with goodwill impairment[24] - The integration of business systems and marketing networks post-acquisition aims to achieve synergy and improve overall performance[25] Research and Development - The company incurred research and development expenses of ¥1,464,601.16 in Q1 2020, down from ¥4,426,155.18 in Q1 2019, reflecting a reduction in R&D investment[49] Financial Management - The company has committed to enhancing the management of accounts receivable to mitigate risks associated with increasing sales and customer credit evaluations[24] - Financial expenses increased by 36.32% year-on-year, primarily due to increased interest expenses on borrowings[17]

Strategic Transformation and Market Position - The company reported a significant strategic transformation, becoming a leading player in the medical information technology sector following the acquisitions of Shanghai Mijian and Shenzhou Shihan[4]. - Recent acquisitions have expanded the company's asset base and business scope, with plans for integration across various operational aspects to enhance synergy and performance[7]. - The company aims to maintain its leading position in the IT service market by enhancing its platform capabilities and offering differentiated services[33]. - The company is committed to strengthening strategic partnerships with domestic platform vendors to promote localization efforts and improve service competitiveness[8]. - The company is focusing on expanding its cloud services and healthcare business through strategic acquisitions[34]. Financial Performance - The company's operating revenue for 2019 was RMB 723,766,459.30, representing a 15.49% increase compared to RMB 626,710,368.71 in 2018[20]. - The net profit attributable to shareholders for 2019 was RMB 43,153,626.44, a significant increase of 111.30% from RMB 20,423,328.33 in 2018[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 41,361,918.65, up 337.74% from RMB 9,448,915.31 in the previous year[20]. - The company's total assets at the end of 2019 were RMB 1,597,976,549.12, an increase of 8.75% from RMB 1,469,367,398.18 at the end of 2018[20]. - The net assets attributable to shareholders increased by 22.49% to RMB 1,089,816,314.06 from RMB 889,734,869.70 in 2018[20]. Revenue and Profitability Trends - Seasonal fluctuations in revenue are evident, with a notable concentration of income occurring in Q4, influenced by clients' budget management and procurement cycles[5]. - The company experienced a seasonal revenue pattern, with the fourth quarter typically generating the highest revenue due to client budgeting cycles[53]. - The revenue from self-controlled software and services has gradually become a key driver for the company's income growth[34]. - The health data service segment generated 377,964,094.07 yuan, accounting for 52.22% of total revenue, with a year-on-year growth of 38.45%[52]. - The gross profit margin for the health data service segment was 48.59%, down from the previous year's margin of 51.03%[55]. Investment and R&D - The company invested a total of 6,600 million yuan in equity assets during the reporting period[35]. - Development expenditures rose by 63.63% year-on-year, reflecting increased R&D investments by subsidiaries[36]. - Research and development expenses increased by 17.24% to 45.62 million yuan, indicating a commitment to innovation[48]. - R&D investment in 2019 amounted to ¥65,881,830.02, representing 9.10% of total revenue[69]. - The number of R&D personnel increased to 253 in 2019, accounting for 31.39% of the workforce[69]. Risk Management and Market Challenges - The company faces increased market competition risks, necessitating ongoing technological and business model innovations to maintain competitiveness[4]. - The company acknowledges potential risks from global economic slowdowns and trade tensions, which could impact IT demand and market competition[8]. - The COVID-19 pandemic has posed short-term operational risks, but it is expected to accelerate the domestic medical information technology development in the long run[8]. - The company emphasizes the importance of talent retention and development to sustain growth amid increasing competition for skilled professionals[6]. Shareholder Returns and Dividend Policy - The company plans to distribute a cash dividend of 0.16 yuan per 10 shares to shareholders, based on a total share capital of 575,295,171 shares[9]. - The cash dividend amount for 2019 represents 21.33% of the net profit attributable to ordinary shareholders, which is 43,153,626.44 CNY[132]. - The total distributable profit for the year is 201,356,233.71 CNY, with the cash dividend accounting for 100% of the profit distribution[130]. - The company has complied with its cash dividend policy and the decision-making process is complete and transparent[128]. - The cash dividend for 2018 was 4,430,053.69 CNY, which was 21.69% of the net profit attributable to ordinary shareholders[132]. Corporate Governance and Compliance - The company has committed to avoiding any competition with its subsidiaries post-restructuring to protect shareholder interests[133]. - The company guarantees to compensate for any losses incurred due to violations of commitments made[134]. - The company has established a consensus action agreement among its actual controllers to ensure unified decision-making on significant operational matters[135]. - The company has committed to ensuring that any related party transactions are conducted fairly and transparently, adhering to legal and regulatory requirements[135]. - The company has reiterated its commitment to transparency and compliance with legal obligations regarding stock ownership and competition[136]. Future Growth and Strategic Focus - The company aims to enhance its product management capabilities and improve user experience to boost market competitiveness[105]. - The company is focused on building a smart healthcare ecosystem, integrating various medical technologies and data analytics to enhance operational efficiency and patient care[115]. - The company plans to leverage national policies supporting domestic IT development, particularly in key sectors like finance, energy, and transportation, to drive growth in its cloud services[111]. - The company is committed to developing a health service platform based on big data analysis, creating unique growth advantages in health data and clinical medical information[109]. - The company aims to establish effective communication channels with national health authorities and industry associations, participating in national-level research associations and preparing to build national laboratories and innovation centers[118].

2019 年第三季度报告全文 荣科科技股份有限公司 1 2019 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人何任晖、主管会计工作负责人李绣及会计机构负责人(会计主管人员)朱迎秋 声明：保证季度报告中财务报表的真实、准确、完整。 2 2019 年第三季度报告全文 Bringspring Science and Technology Co.,Ltd. 2019 年第三季度报告 2019 年 10 月 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | | 总资产（元） | 1,489,618,908.87 | 1,469,367,398.18 | | 1.38% | | 归属于上市公司股东的净资产（元） | 1,067,85 ...

1 关于参加辽宁辖区上市公司投资者网上集体接待日活动的公告 证券代码：300290 证券简称： 荣科科技 公告编号：2019-100 荣科科技股份有限公司 关于参加辽宁辖区上市公司投资者网上集体接待日 活动的公告 本公司及董事会成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 为进一步加强与广大投资者的互动交流，荣科科技股份有限公司（以下简称"公 司"）将参加"2019 年辽宁辖区上市公司投资者网上集体接待日"活动，现将有关 事项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举行， 投资者可以登陆 "全景·路演天下"网站（http://rs.p5w.net）参与公司本次投 资者集体接待日活动，时间为 2019 年 9 月 19 日（周四）14:30 至 17:00。 届时公司高管将通过网络在线交流的形式，与投资者就公司治理、经营状况、 发展战略、风险防控、投资者保护等投资者关注的问题进行沟通。 欢迎广大投资者积极参与。 荣科科技股份有限公司董事会 二〇一九年九月十七日 ...

Strategic Transformation and Acquisitions - The company has achieved substantial progress in strategic transformation, becoming a leading player in the medical information technology sector following the acquisitions of Shanghai Mijian and Shenzhou Shihan[6]. - The company has completed acquisitions of Mijian Information and Shenzhou Shihan, which may lead to increased goodwill and potential impairment risks if market conditions deteriorate[11]. - The company aims to integrate its business systems and enhance operational efficiency following recent acquisitions, which could improve profitability and core competitiveness[11]. Financial Performance - Total revenue for the reporting period reached ¥294,783,892.97, representing a 32.34% increase compared to ¥222,754,134.26 in the same period last year[25]. - Net profit attributable to shareholders was ¥8,932,140.63, up 39.82% from ¥6,388,117.21 year-on-year[25]. - The net profit after deducting non-recurring gains and losses surged by 502.39%, amounting to ¥8,708,777.87 compared to ¥1,445,714.57 in the previous year[25]. - The company's total assets increased by 0.84% to ¥1,481,663,109.93 from ¥1,469,367,398.18 at the end of the previous year[26]. - Shareholders' equity rose by 19.50%, reaching ¥1,063,243,313.68 compared to ¥889,734,869.70 at the end of the previous year[26]. Research and Development - The company is focused on increasing research and development investments to drive product innovation and customer-centric solutions[6]. - The company is focusing on smart healthcare and health data as key development areas, with a joint research center established for early detection of cardiovascular diseases[34]. - The company plans to deepen research in big data and system integration, focusing on urban management and government services[36]. Customer Experience and Market Strategy - The company plans to enhance its product lines and improve customer experience to mitigate risks associated with market competition and seasonal fluctuations[6][7]. - The company has emphasized the importance of talent retention and has implemented incentive mechanisms to attract and retain high-quality personnel amid increasing competition for skilled workers[9]. - The company is committed to integrating its various medical business units to create a unique competitive advantage in clinical medical information and health data analysis[49]. Cash Flow and Financial Management - The net cash flow from operating activities was negative at approximately -¥103.27 million, a decline of 162.41% year-over-year, indicating higher cash outflows than inflows[54]. - The net cash flow from financing activities significantly improved to approximately ¥188.44 million, a 1,709.15% increase, mainly due to increased investment inflows[54]. - The company's cash and cash equivalents decreased by approximately 88.41% to -¥80.81 million, attributed to higher cash expenditures for investments and operational costs[54]. Shareholder and Equity Information - The company did not distribute cash dividends or issue bonus shares for the half-year period[12]. - The company held two shareholder meetings during the reporting period, with investor participation rates of 49.38% and 47.43% respectively[82]. - The largest shareholder, Liaoning Guoke Industrial Co., Ltd., holds 26.60% of shares, totaling 147,279,042 shares, with 54,100,000 shares pledged[131]. Compliance and Risk Management - The company has strengthened its internal control system to ensure compliance, asset safety, and the integrity of financial reporting, while reducing operational risks[52]. - The company has no major litigation or arbitration matters during the reporting period[88]. - The company has not experienced any significant changes in the feasibility of its fundraising investment projects[73]. Operational Efficiency and Cost Control - The company actively promoted comprehensive budget management to control costs through detailed planning and employee participation, enhancing overall strategic goal achievement[50]. - Operating costs increased to approximately ¥188.19 million, a rise of 24.53% compared to the previous year, primarily driven by business growth[54]. - Research and development expenses rose by 51.22% to approximately ¥31.42 million, reflecting increased investment in R&D activities[54]. Capital Structure and Financing - The company raised a total of 168 million RMB in funding during the reporting period, including 160 million RMB from issuing shares and 8.42 million RMB from stock options and restricted stock[51]. - The total amount of raised funds is CNY 330.90 million, with CNY 126.90 million utilized during the reporting period and a cumulative total of CNY 294.90 million invested[70]. - The company has maintained strict management of unused raised funds, which are stored in a dedicated bank account[73].

Acquisition and Integration - The company completed the acquisition of 100% equity of Shanghai Mijian and Beijing Shenzhou Shihan, enhancing its competitive position in the medical information technology sector[11]. - The company is focused on integrating its operations post-acquisition to enhance profitability and core competitiveness through synergies in various business aspects[12]. - The company acquired 100% equity of Beijing Shenzhou Shihan Technology Co., Ltd. for 28 million yuan[40]. - The company completed the acquisition of 100% equity in Shenzhou Shihan, which has become a new profit growth point, increasing the total shares to 338,572,507[51]. - The company has committed to maintaining its independence post-acquisition, ensuring no related party transactions or competition arise[117]. Financial Performance - The company's operating revenue for 2018 was CNY 626.71 million, representing a 49.70% increase compared to CNY 418.66 million in 2017[26]. - The net profit attributable to shareholders for 2018 was CNY 20.42 million, an increase of 8.52% from CNY 18.82 million in 2017[26]. - The net profit after deducting non-recurring gains and losses decreased by 45.70% to CNY 9.45 million in 2018 from CNY 17.40 million in 2017[26]. - The net cash flow from operating activities surged by 409.19% to CNY 95.09 million in 2018, compared to CNY 18.67 million in 2017[26]. - The total assets at the end of 2018 reached CNY 1.47 billion, a 39.35% increase from CNY 1.05 billion at the end of 2017[26]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 0.12 RMB per share and a stock bonus of 5 shares for every 10 shares held, based on a total share capital of 369,171,141 shares[14]. - The cash dividend represents 21.69% of the net profit attributable to ordinary shareholders, which is 20,423,328.33 CNY for 2018[115]. - The cash dividend payout ratio for 2018 is 100% of the total profit distribution[111]. - The company has maintained a consistent cash dividend policy over the past three years[115]. Research and Development - The company aims to achieve a leading position in differentiated innovation within its niche market through substantial investment in product technology[6]. - Research and development expenses reached ¥38,907,431.66, reflecting a year-on-year increase of 55.63% due to the inclusion of new subsidiaries in the consolidated financial statements[52]. - R&D investment amounted to ¥53,784,782.43, representing 8.58% of total revenue in 2018[71]. - The company aims to enhance its R&D capabilities by leveraging strategic resources from its Boston-based research institute and integrating cutting-edge technologies such as AI and big data to drive innovation in healthcare[96]. Market Position and Strategy - The company was ranked among the top 500 solution providers in China and recognized as one of the top ten ISVs in the medical industry, indicating strong market positioning[47]. - The company is focused on creating a one-stop health O2O service platform to deliver quality healthcare resources and innovative management concepts[36]. - The company plans to continue leveraging capital markets for strategic investments and acquisitions to support its overall development strategy[51]. - The company is committed to improving its internal control systems through regular audits and enhanced supervision to ensure sustainable development and risk management[99]. Employee Engagement and Talent Management - The company emphasizes the importance of talent retention amidst increasing competition for skilled professionals, implementing incentive mechanisms to enhance employee satisfaction[9]. - The company launched an incentive plan for stock options and restricted stock to motivate employees and align with business goals[49]. - The total employee count is 783, with 288 in the parent company and 495 in major subsidiaries[195]. - Employee compensation totaled CNY 149 million, accounting for 23.37% of total company costs[196]. Risk Management and Compliance - The company has enhanced its internal control system to mitigate operational risks and improve management efficiency[51]. - The company has committed to avoiding any competition with its main business and has ensured that it and its controlled enterprises are not engaged in any competitive activities in China or abroad[117]. - The company has established a performance guarantee mechanism, where compensation will be provided if the actual net profit does not meet the promised figures[117]. Product Development and Innovation - The company launched a new smart ward product in 2018, providing an integrated software and hardware solution for inpatient information services[35]. - The company is developing a health big data service platform aimed at chronic disease patients, integrating resources from hospitals, community service centers, and health management centers[70]. - The company is enhancing its surgical anesthesia clinical information system by adding a day surgery module to increase business opportunities and market share[70]. - The company is actively pursuing new product development and technological advancements to stay competitive in the market[122]. Corporate Governance and Management - The company has independent directors with extensive experience in finance and technology, enhancing governance and strategic oversight[190]. - The financial team is led by a qualified CFO with a strong background in auditing and financial management, ensuring accurate financial reporting[191]. - The company completed the election of the fourth board of directors and supervisory board, updating the resumes of relevant directors, supervisors, and senior executives[191]. - The management team includes professionals with significant experience in human resources and operations, contributing to effective organizational management[190].

2019 年第一季度报告全文 荣科科技股份有限公司 Bringspring Science and Technology Co.,Ltd. 2019 年第一季度报告 2019 年 04 月 1 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人何任晖、主管会计工作负责人李绣及会计机构负责人(会计主管人员)朱迎秋 声明：保证季度报告中财务报表的真实、准确、完整。 2 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 137,522,293.94 | 95,698,962.45 | 43.70% | | 归属于上市公司股东的净利润（元） | 7,037,897.03 | 5,474,4 ...